Methods for Preventing Posterior Capsular Opacification
The present invention relates to a composition comprising a sterile ophthalmic composition, which comprises one or more agents capable of inhibiting lens epithelial proliferation dissolved in a physiologically isotonic solution. The present invention also relates to a method of preventing capsular opacification comprising by using said composition. The method comprises the steps of: creating an incision within an eye and a capsulorhexis in a capsular bag of said eye; inserting at least a portion of cannula in said capsulorhexis; separating the natural crystalline lens from the capsular bag by injecting through a cannula a sterile ophthalmic composition in a manner that generates a space between the capsular bag and the natural crystalline lens wherein said composition comprises one or more agents capable of inhibiting lens epithelial proliferation dissolved in a physiologically isotonic solution; retaining the composition in said space between the capsule and the natural crystalline lens for a sufficient time for said composition to effectively kill or render non-proliferative lens epithelial cells in or adjacent to said space; removing the lens and said composition; inserting an implant into the capsular bag.
1 .- 32 . (canceled)
33 . A method of preventing capsular opacification comprising:
a) creating an incision within an eye and a capsulorhexis in a capsular bag of the eye;
b) inserting at least a portion of a cannula in the capsulorhexis;
c) separating the natural crystalline lens from the capsular bag by hydrodissection wherein a sterile ophthalmic composition is injected through the cannula and in a manner that generates a space between the capsular bag and the natural crystalline lens, the composition comprising one or more agents capable of inhibiting lens epithelial proliferation dissolved in a physiologically isotonic solution;
d) retaining the composition in the space between the capsule and the natural crystalline lens for a time period of less than 10 minutes to effectively kill or render non-proliferative lens epithelial cells in or adjacent to the space;
e) removing the lens and the composition; and
f) inserting an implant into the capsular bag.
34 . A method according to claim 33 , wherein the one or more agents include one or more cytotoxic agents.
35 . A method according to claim 34 , wherein the one or more cytotoxic agents comprises one or more of saporin, ricin, methotrexate, 5-fluorouracil, daunomycin, doxorubicin, mitoxanthrone, vinca alkaloids, vinblastine, colchicine, cytochasins, monensin, mitomycin and ouabain.
36 . A method according to claim 34 , wherein the one or more cytotoxic agents comprises 5-fluorouracil.
37 . A method according to claim 34 , wherein the one or more cytotoxic agents comprises saporin.
38 . A method according to claim 34 , wherein the one or more cytotoxic agents comprises mitomycin.
39 . A method according to claim 34 , wherein the one or more cytotoxic agents comprises doxorubicin.
40 . A method according to claim 33 , wherein the one or more agents comprises a molecule of nucleic acid comprising a gene coding for an agent inducing the death of the lens epithelial cells, under a transcriptional control specific to said cells.
41 . A method according to claim 33 , wherein the one or more agents comprises one or more basement membrane binding agents conjugated to one or more cytotoxic agents.
42 . A method according to claim 33 , wherein the one or more agents comprises surfactant.
43 . A method according to claim 33 , wherein the one or more agents comprises divalent cation chelator.
44 . A method according to claim 33 , wherein the one or more agents comprises analogs or antibodies directed against cell attachment receptors.
45 . A method according to claim 33 , wherein the implant is an artificial lens.
46 . A method according to claim 45 , wherein the lens is a foldable lens or non-foldable lens made from a material comprising a homo- or co-polymer of acrylate, methacrylate or other substituted acrylate, or polysiloxane.
47 . A method according to claim 45 , wherein the lens is a foldable lens or non-foldable lens made from polymethylmethacrylate.
48 . A method according to claim 33 , wherein the implant comprises an injectable ophthalmic-acceptable material that can undergo crosslinking to a final lens implant following its injection into the capsular bag.
49 . A method according to claim 33 , wherein the composition is retained in the space between the capsule and the natural crystalline lens for a time period of less than 3 minutes to effectively kill or render non-proliferative lens epithelial cells in or adjacent to the space.
50 . A method according to claim 33 , wherein the composition is retained in the space between the capsule and the natural crystalline lens for a time period of less than 30 seconds to effectively kill or render non-proliferative lens epithelial cells in or adjacent to the space.